Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by StockNews.com

Heron Therapeutics (NASDAQ:HRTX) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday.

Separately, Needham & Company LLC restated a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Friday.

Heron Therapeutics Price Performance

NASDAQ HRTX opened at $2.47 on Friday. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93. The firm has a market cap of $375.67 million, a price-to-earnings ratio of -13.72 and a beta of 1.60. The company has a fifty day moving average price of $1.69 and a 200-day moving average price of $1.71.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. On average, research analysts anticipate that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Heron Therapeutics

Several institutional investors have recently added to or reduced their stakes in HRTX. Wealth Enhancement Advisory Services LLC lifted its holdings in Heron Therapeutics by 21.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 7,927 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Heron Therapeutics by 456.5% during the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 84,205 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Heron Therapeutics by 18.4% during the third quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock valued at $1,020,000 after purchasing an additional 79,680 shares during the last quarter. King Wealth Management Group lifted its holdings in Heron Therapeutics by 52.3% during the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 8,000 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Heron Therapeutics during the third quarter valued at about $72,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.